Editorial: Taking medical advice

Editorial: Taking medical advice

Richard Jory

The structured products industry is home to so many debates that it can sometimes give you a headache. Are the products complex? Should they be treated like any other investment? Are they like cars? Do they ‘do what they say on the tin'? Should grandmothers be allowed to buy them?

All good questions for financial regulators, but are the watchdogs the ones best equipped to come up with the answers and create appropriate legislation? Surely retail investors would be better served by legislators

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...


You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: